Daily ReportOct 7, 2026
Sepsis, October 7 edition
We read 37 papers and selected 3.
Summary
Today's most impactful sepsis research spans mechanistic biology, causal treatment evaluation, and translational therapeutics. Notably, early-life microbiota were shown to program epithelial calprotectin production that protects neonates from sepsis, while a target trial emulation suggested that vasopressin benefit may depend strongly on norepinephrine dose and shock severity; a randomized trial also reported lower 28-day mortality with anisodamine hydrobromide.
Research Themes
- Microbiota-driven neonatal immune protection
- Severity-adapted vasopressor strategies
- Randomized pharmacologic treatment of septic shock
Selected Articles
1. Early-life microbiota direct an epithelial S100 program required for neonatal immunity.
Using neonatal mouse models, this study identified commensal microbiota exposure at birth as a trigger for intestinal epithelial S100A8/S100A9 calprotectin production. Loss of microbiota colonization or calprotectin expression increased susceptibility to sepsis and death, whereas exogenous calprotectin rescued microbiota-depleted pups, providing a causal link between early microbial colonization and neonatal antimicrobial defense.
Impact: This paper identifies a previously underappreciated epithelial mechanism through which initial microbiota exposure establishes neonatal resistance to invasive infection. It suggests that epithelial antimicrobial programs, rather than immune-cell maturation alone, may be actionable targets for preventing neonatal sepsis.
Clinical Implications: The findings support investigation of microbiota-preserving strategies, epithelial antimicrobial supplementation, or calprotectin-based interventions for high-risk neonates. Translation requires confirmation in human neonates and careful assessment of developmental safety, dosing, and effects on microbiome composition.
Key Findings
- Initial commensal microbiota exposure induced S100A9 expression and calprotectin production by neonatal intestinal epithelial cells.
- Impaired microbiota colonization or calprotectin expression increased neonatal susceptibility to sepsis and postinfection death.
- Calprotectin administration rescued microbiota-depleted neonatal mice from lethal infection.
Methodological Strengths
- The study combined microbiota manipulation, epithelial cell-specific analysis, infection models, and rescue experiments.
- The rescue phenotype provided functional evidence supporting a causal role for calprotectin rather than only an associative biomarker relationship.
Limitations
- The principal mechanistic evidence was generated in neonatal mice, and species differences may limit direct translation to human infants.
- The provided abstract does not report the complete cohort size, duration of follow-up, or detailed dose-response and safety data for calprotectin administration.
Future Directions: Future studies should validate the epithelial S100–calprotectin pathway in human neonatal tissues and prospective infant cohorts, define the responsible microbial taxa and metabolites, and test microbiota-based or calprotectin-based interventions in carefully controlled translational models.
Despite appreciation that neonatal immune responses differ markedly from those of adults, the mechanisms that enable early-life immunity remain poorly understood. Here, we find that healthy newborn mice express high concentrations of the S100 calcium-binding protein A8/A9 (S100A8/S100A9) antimicrobial heterodimer calprotectin and that this early up-regulation in the intestine is driven by initial exposure to commensal bacteria. Impaired calprotectin expression or microbiota colonization at birth increased susceptibility of neonatal mice to sepsis and death postinfection; however, calprotectin administration rescued microbiota-depleted pups from infection.
2. Timing of Vasopressin Initiation in Sepsis Patients on Norepinephrine: A Target Trial Emulation.
This large retrospective analysis emulated a target trial to reduce immortal time bias when evaluating early vasopressin initiation. Benefit appeared most consistent in patients receiving norepinephrine-equivalent doses around 0.25 micrograms/kg/min, whereas initiation above 0.5 micrograms/kg/min was associated with increased early mortality, although residual confounding by shock severity remains possible.
Impact: The study challenges a uniform vasopressin-starting threshold by demonstrating time-varying and severity-dependent associations. Its use of target trial emulation addresses an important bias in observational vasopressor research and generates a clinically testable treatment-window hypothesis.
Clinical Implications: The findings may support consideration of vasopressin before norepinephrine requirements become very high, particularly around 0.25 micrograms/kg/min, but they should not be used as a definitive bedside threshold. Prospective trials are needed before changing sepsis or septic shock treatment guidelines.
Key Findings
- The analysis included 5,461 patients with septic shock from the MIMIC-IV 2.2 database.
- A delayed survival benefit was observed in the subgroup with norepinephrine-equivalent doses above 0.25 micrograms/kg/min.
- Early vasopressin initiation was associated with increased mortality during the first 48 hours when norepinephrine requirements exceeded 0.5 micrograms/kg/min, with the strongest signal above 0.75 micrograms/kg/min.
Methodological Strengths
- The clone-censor-weight target trial emulation explicitly addressed immortal time bias and time-varying treatment effects.
- Analyses were stratified across clinically meaningful norepinephrine-equivalent dose thresholds and included sensitivity and subgroup analyses.
Limitations
- The retrospective database design cannot eliminate confounding by indication or residual confounding related to shock severity.
- The higher-dose early mortality association may reflect treatment of patients who were already deteriorating rather than direct vasopressin toxicity, and confidence intervals for long-term benefit were wide.
Future Directions: A prospective, stratified randomized trial should evaluate vasopressin initiation at prespecified norepinephrine dose ranges, incorporate dynamic shock phenotyping, and measure renal, ischemic, and long-term patient-centered outcomes.
BackgroundThe optimal timing for initiating vasopressin in septic shock remains uncertain, with conflicting evidence potentially arising from variations in patient severity and methodological limitations such as immortal time bias. This study aimed to evaluate the time-varying effect of early vasopressin initiation across a spectrum of baseline norepinephrine dose requirements.MethodsWe included 5461 patients with septic shock from the MIMIC-IV 2.2 database. A target trial emulation framework was applied, using a clone-censor-weight approach with inverse probability of censoring weighting to address immortal time bias.
3. Anisodamine hydrobromide reduces 28-day mortality in septic shock: a randomized controlled.
In a prospective randomized trial of 296 patients with septic shock, anisodamine hydrobromide plus standard therapy reduced 28-day mortality compared with standard therapy alone. The mortality association was partly mediated by lactate and lactate-clearance measures at 24 hours, supporting a potential hemodynamic or metabolic mechanism while requiring confirmation in larger, rigorously reported trials.
Impact: This is one of the few randomized evaluations in the provided dataset to report a mortality benefit from a pharmacologic adjunct in septic shock. The mediation analysis links the observed outcome to an early, clinically measurable physiologic response and provides a mechanistic hypothesis for future trials.
Clinical Implications: Anisodamine hydrobromide may be considered a candidate adjunctive therapy for septic shock, but the reported mortality benefit should not prompt routine adoption before independent replication. Future studies should clarify patient selection, dosing, adverse effects, blinding, and interaction with contemporary vasopressor and resuscitation strategies.
Key Findings
- A total of 296 patients with septic shock were randomized equally to anisodamine hydrobromide plus standard therapy or standard therapy alone.
- Anisodamine hydrobromide reduced 28-day mortality with a hazard ratio of 0.64, 95% confidence interval 0.43–0.95, and P = 0.028.
- Lactate at 24 hours and 24-hour lactate-clearance rate mediated 14.1% and 17.3% of the total treatment effect, respectively.
Methodological Strengths
- The prospective randomized allocation and prespecified primary mortality outcome directly addressed a clinically important treatment question.
- Causal mediation analyses connected treatment assignment with early lactate dynamics and included a complete-case sensitivity analysis.
Limitations
- The sample size was moderate, and the provided abstract does not report key trial features such as blinding, allocation concealment, registration, or multicenter participation.
- The mortality finding requires independent replication, and mediation analysis cannot by itself establish that lactate changes are on the causal pathway.
Future Directions: Larger multicenter randomized trials with transparent registration, blinded outcome assessment, detailed safety reporting, and contemporary standard-of-care comparators should confirm mortality effects and identify the septic shock phenotypes most likely to benefit.
BACKGROUND: This randomized controlled trial evaluated whether anisodamine hydrobromide reduces 28-day mortality in septic shock and whether this effect is mediated by lactate and lactate clearance. METHODS: In this prospective randomized controlled trial, 296 patients with septic shock were randomly assigned to receive anisodamine hydrobromide plus standard therapy (n = 148) or standard therapy alone (n = 148). The primary outcome was 28-day all-cause mortality. Causal mediation analyses were performed to assess the mediating roles of lactate and lactate clearance rate at 24, 48, and 72 h.